Stay updated on Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial page.

Latest updates to the Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial page
- Check4 days agoChange DetectedThe general government funding notice about operating status was removed; otherwise the study record history content remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe two screenshots show the same Record History table with no new version data or changes to core content. Only minor UI/visual adjustments are evident.SummaryDifference0.1%

- Check47 days agoChange DetectedAdded a government-operating-status notice and a version bump to v3.2.0; removed the previous version label v3.1.0.SummaryDifference10%

- Check54 days agoChange DetectedUpdate: version bumped from v3.0.2 to v3.1.0.SummaryDifference0.2%

- Check68 days agoChange DetectedPage revision updated from v3.0.1 to v3.0.2; the Back to Top element was removed, with no substantive content changes otherwise.SummaryDifference0.6%

- Check75 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.SummaryDifference0.6%

Stay in the know with updates to Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial page.